CA Patent

CA3258444A1 — Eravacycline for treating cancer

Assigned to BG Negev Technologies and Applications Ltd · Expires 2023-12-07 · 2y expired

What this patent protects

Methods of treating pancreatic cancer or metastasis thereof by administering eravacycline or a derivative thereof are provided. Pharmaceutical compositions including eravacycline or a derivative thereof for use in treating pancreatic cancer or a metastasis thereof are also provid…

USPTO Abstract

Methods of treating pancreatic cancer or metastasis thereof by administering eravacycline or a derivative thereof are provided. Pharmaceutical compositions including eravacycline or a derivative thereof for use in treating pancreatic cancer or a metastasis thereof are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA3258444A1
Jurisdiction
CA
Classification
—
Expires
2023-12-07
Drug substance claim
No
Drug product claim
No
Assignee
BG Negev Technologies and Applications Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.